Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

Stopped early · Phase 1/Phase 2

Conditions studied: Carcinoid Syndrome

In brief

Evaluate the pharmacokinetics, safety and efficacy of an octreotide implant for the treatment of the symptoms of carcinoid syndrome.

Key facts

Study ID

NCT00884715

Run by

Endo USA Inc., a Keenova Therapeutics Company

People needed

10

Starts

2009-07-01

Expected to finish

2011-12-01

Last updated by the study team

2013-09-20

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• histologically confirmed tumor
• documented evidence of carcinoid syndrome
• life expectancy of at least 6 months
• previous positive octreotide scan
• received stable doses of octreotide injections
• performance status of 0-2 on the ECOG performance scale

You may not qualify if…

• poorly differentiated or high grade neuroendocrine tumor
• significant cv, hepatic, renal or other disease

Where it is running

• Study site — Iowa City, Iowa, United States
• Study site — Boston, Massachusetts, United States
• Study site — Burlington, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.